Not All Government Funding Is Useless — This One Is Built for Healthcare Founders Ready to Scale

Let’s get the obvious out of the way. When most startup founders hear “government funding program,” they picture a slow, confusing process that ends with either nothing or a loan they could have gotten from a bank anyway.

That instinct isn’t always wrong. But it’s also why most founders in healthcare — a sector where health tech alone attracted $828 million in the first half of 2025, making it the second most funded vertical after fintech — completely miss a program that was specifically designed for them. One that doesn’t take your equity, doesn’t saddle you with crushing debt, and has already backed over 60 real healthcare solutions across India.

It’s called SAMRIDH. And if you’re building in healthtech, medtech, diagnostics, or primary care — and you’ve moved past the idea stage into something that actually works — this might be the most underrated funding path available to you in 2026.

Wait, Which SAMRIDH? (There Are Actually Two)

Before we go further, let’s clear up a common confusion. There are two separate programs with the name SAMRIDH, and mixing them up is one of the most common mistakes founders make.

This guide focuses primarily on the SAMRIDH Healthcare Blended Finance Facility — because for healthcare founders at the scaling stage, it solves a very specific and painful problem.

The Problem SAMRIDH Was Built to Solve

Here’s the uncomfortable reality of healthcare entrepreneurship in India. You can build an incredible product — an AI that reads chest X-rays, a portable ECG device, a rural health network — and still struggle to scale it. Not because the technology doesn’t work. But because healthcare has a unique funding gap that other sectors don’t face.

In India, public spending in the health sector has been historically low, with the government contributing approximately 1.8 percent of the GDP toward public health care, as opposed to the global average of about 10 percent. Access to affordable capital, especially commercial capital, is a bottleneck to scaling up. Often termed as the second valley of death, innovators are unable to access resources for scaling proven high-impact solutions.

Private equity and VC money in healthcare exists, but these investments have largely gone into tier-1 markets and not necessarily toward improving accessibility and affordability for the vulnerable masses. Meanwhile, the current funding environment, marked by increased investor selectivity, means that only ventures with proven operational depth and clear revenue models are likely to secure substantial capital.

So if you’re a healthcare startup doing meaningful work in smaller cities, rural areas, or serving low-income communities, you’re caught in a trap: VCs want tier-1 margins, banks want collateral you don’t have, and pure grants are too small to fuel real scale.

This is exactly the gap SAMRIDH was designed to fill.

How SAMRIDH Actually Works (The Blended Finance Model)

SAMRIDH doesn’t just hand you a cheque. It uses something called “blended finance” — which sounds complicated but is actually a simple and powerful concept.

Blended finance is an approach towards financing where catalytic funding (e.g grants and concessional capital) from public and philanthropic sources is utilized to mobilize additional private sector investment to realize social goals and outcomes.

In practice, here’s what that means for you as a founder:

Think about what this means. You’re getting grant money (that you don’t repay), combined with low-cost debt, combined with technical support — and nobody takes a piece of your company in return. For a healthcare startup burning through runway while trying to scale into hospitals and district health systems, this is an extraordinarily favorable structure.

And the leverage effect is remarkable. Financially, SAMRIDH has leveraged USD $10 for every USD $1 of philanthropic capital deployed. That 10x multiplier means your SAMRIDH support doesn’t just fund your current operations — it makes you dramatically more attractive to commercial investors who come next.

What SAMRIDH Has Actually Funded (Not Theory — Real Startups)

This is where most founders start paying attention. Because government programs sound great in theory. The question is: do they actually back real startups solving real problems?

To date, SAMRIDH has aided over 60 entities, supported around 1,300 healthcare facilities, reached out to 43 million people, and trained over 27,000 medical staff and community healthcare workers.

The portfolio, publicly listed on SAMRIDH’s website, spans an impressive range of healthcare challenges:

• Qure.ai’s qXR — AI-Powered Medical Image Reading Technology deployed pan-India. SAMRIDH’s support enabled them to deploy their AI-driven chest X-ray screening solution in rural and semi-urban hospital settings.
• Spandan by Sunfox Technologies — A portable ECG monitor deployed across Uttar Pradesh, Uttarakhand, Jammu & Kashmir and Delhi. The Dehradun-based startup had previously raised INR 5 Cr from USAID via SAMRIDH Health and LetsVenture, bringing its total funding to INR 20 Cr. Sunfox’s flagship product, Spandan, is a portable smartphone-based ECG device that has been used in 20 countries and has saved over 10,000 lives.
• Carenation — Remote Tele-ICUs for Critical Care, pan-India with focus on Rajasthan, Telangana, Kerala, Karnataka & Tamil Nadu
• Blackfrog Technologies — The impact funding and risk guarantee received from SAMRIDH has been instrumental for Blackfrog to raise commercial capital from financial institutions. This has enabled us to scale up our manufacturing capacity for Emvólio and cater to markets across India and overseas.
• Drone-based medical product delivery in Arunachal Pradesh and Odisha — supply chain innovation for the most remote areas
• EzeCheck — IoT-enabled Non-invasive blood-free hemoglobinometer for rapid Anemia Detection
• AI-powered, radiation-free breast cancer detection

And then there’s the story that best illustrates what SAMRIDH actually does for a founder’s trajectory.

The Karma Primary Healthcare Story

Karma Primary Healthcare, a healthcare enterprise, leverages technology to address the primary health needs of vulnerable populations in semi-urban and rural areas. Karma delivers a sustainable rural healthcare model that broadens the scope of primary healthcare services and reduces out-of-pocket health expenses. Through e-Doctor Clinics, supported by qualified medical professionals, Karma provides access to specialty care that is typically difficult to access in rural areas.

In 2021, SAMRIDH provided Karma Primary Health with US$ 111,000 in result-based financing support. This enabled Karma to expand the continuum of care to low-income neighborhoods in Rajasthan, Madhya Pradesh, and Haryana. Karma was able to establish three additional primary healthcare clinics, resulting in a 45% increase in the number of covered districts and a remarkable 61% surge in patient visits.

But here’s the punchline: With USAID’s support, Karma Primary Healthcare attracted other investment capital from international investors, donors, philanthropies, and multilateral agencies, to expand its services and improve business performance. Karma has demonstrated impressive results, with a revenue growth of 158% and a valuation increase of approximately 150%. Karma has now reached over 46,000 individuals through tele consultation and conducted over 33,000 e-clinic consultations. It has also expanded its operations into new geographic regions, including Rajasthan, Madhya Pradesh, and Haryana, reaching over 172,000 people annually in the catchment areas of its 25 clinics.

That’s the SAMRIDH model in action: strategic capital unlocks commercial capital, which unlocks scale, which unlocks impact. The initial SAMRIDH support wasn’t just about the dollars — it was the credibility signal that made everything after it possible.

Who Qualifies? (The Eligibility Bar Is Higher Than You Think)

Here’s where you need to be honest with yourself. SAMRIDH is not for idea-stage founders. It’s not for startups that just got their first prototype working last month. The bar is deliberately set at a stage where you’ve already proven something real.

That ₹3 crore revenue minimum and 30% gross margin requirement tell you something important about SAMRIDH’s philosophy. They’re not funding experiments. They’re funding businesses that have already proven the product works, the customers exist, and the unit economics make sense — but need capital to go from serving 5 districts to serving 50.

What SAMRIDH Is Looking For (This Is Where Most Founders Fail)

Meeting the eligibility criteria gets you through the door. But the evaluation itself is about something deeper. Once you share your application and meet the basic selection criteria, the team gets in touch to better understand your proposal, the problem that you are trying to solve and the proposed approach. Through a series of conversations, they will determine if the project is a good two-way fit to be funded by SAMRIDH.

The key evaluation dimensions, based on SAMRIDH’s published criteria:

• Does your solution actually solve something real? — Not a marginal improvement over existing tools. A genuine healthcare gap that affects vulnerable populations.
• Can it scale across India? — A solution that works in one hospital in Mumbai is different from one that works in 200 primary health centres across Madhya Pradesh.
• Is it ready for market use? — Techno-commercial aspects of your solution, including but not limited to, regulatory approvals, market sizing, market access, ease of integration into current workflows, affordability of the solution.
• What’s the scale of impact? — Scale of impact demonstrated by number of beneficiaries, increased access to affordable healthcare, cost savings to the system, reduction in Out of Pocket Expenditure.

As SAMRIDH’s Project Director put it: “SAMRIDH recognizes that not all enterprises have uniform needs, and therefore require customized financial solutions. Our agile structure enables us to navigate evolving regulatory landscapes and implement a result-oriented approach.”

The Specific Focus Areas (Is Your Startup in the Zone?)

SAMRIDH is inviting applications from healthcare enterprises working towards strengthening India’s critical health systems, facilitating training and capacity building of healthcare workers, driving innovation in the medical device market, addressing co-morbidities, improving India’s diagnostic capacity, strengthening supply chain and logistics for delivery, or addressing mental health challenges.

Based on the portfolio and published priorities, the areas that fit best:

• Diagnostics — AI-powered imaging, point-of-care testing, rapid screening tools, molecular diagnostics
• Medical devices — Portable monitoring equipment, low-cost surgical tools, tele-ICU systems
• Primary healthcare delivery — Rural clinic networks, e-clinics, community health models
• Health infrastructure — Oxygen plants, emergency response platforms, hospital capacity
• Supply chain — Cold chain solutions, drone delivery, pharmaceutical logistics
• Healthcare worker training — Skilling platforms, capacity building for frontline workers
• NCDs — Screening, Diagnosis, Management and Treatment of NCDs including Diabetes, Hypertension, Chronic Kidney Disease, Obesity, Mental Health

If your startup improves access, affordability, or quality of healthcare for underserved populations — you’re in the zone.

The Hidden Advantage Most Founders Miss

Here’s what the SAMRIDH portfolio stories keep showing: the money matters, but the signal matters more.

When Blackfrog Technologies received SAMRIDH support, it wasn’t just the capital that changed their trajectory — the impact funding and risk guarantee received from SAMRIDH was instrumental for Blackfrog to raise commercial capital from financial institutions. When SAMRIDH supported Karma Healthcare, the result was that Karma attracted other investment capital from international investors, donors, philanthropies, and multilateral agencies.

This is the pattern: SAMRIDH funding acts as a credibility stamp. When a USAID-backed, NITI Aayog-partnered facility validates your healthcare solution, it sends a signal to every other funder in the ecosystem — commercial banks, impact investors, venture funds, DFIs — that you’ve been vetted by serious people against serious criteria.

SAMRIDH has catalyzed diverse partnerships with over 100 ecosystem players from the government, financial institutions, philanthropies, incubators, academia and industry associations. Key partners include Indian Institute of Technology (IIT-D), the Principal Scientific Advisor to the Government of India, the National Health Authority, Rockefeller Foundation, IndusInd Bank, Axis Bank, Caspian, and NATHEALTH.

That network becomes your network when you enter the portfolio.

Where Most Founders Go Wrong

Based on the published evaluation criteria and the FAQ on SAMRIDH’s application portal, these are the most common mistakes:

1. They Apply Too Early

If your revenue is below ₹3 crore, your product is still in pilot, or you haven’t hit TRL 7, you don’t qualify for the healthcare blended finance facility yet. Don’t waste your time or theirs. Focus on getting to product-market fit first, then apply when you’re genuinely ready to scale.

2. They Don’t Understand the “Two-Way Fit”

Applications will be assessed for a two-way fit between the proposed solution and SAMRIDH. It is strongly suggested applicants invest time to understand SAMRIDH’s purpose and priorities, to identify synergies with their proposed solution. This isn’t a generic grant. They’re looking for alignment with specific national health priorities. Read the portfolio. Understand their focus areas. Frame your solution in terms of the healthcare gaps they care about.

3. They Think It’s Just About Money

SAMRIDH also provides healthcare enterprises with comprehensive support, from business advisory services to technical assistance, enabling them to create financially viable solutions that foster sustainable impact. If you only want a cheque, you’re undervaluing what SAMRIDH actually offers. The market access, the partnership network, the technical assistance — these often matter more than the capital itself.

4. They Treat It Like “Apply Everywhere”

SAMRIDH is not a form you blast out alongside 20 other applications. The evaluation involves multiple conversations, deep review, and due diligence. Come prepared with your impact data, your financials, your scale-up plan, and a clear articulation of who you serve and why it matters.

Also Worth Knowing: The MeitY SAMRIDH Accelerator

If you’re an earlier-stage healthtech startup — pre ₹3 crore revenue, still building your product — the MeitY SAMRIDH accelerator programme may be a better fit for where you are right now.

Under the SAMRIDH programme, 186 accelerators submitted Expressions of Interest, leading to the selection of 43 top accelerators across 16 states. SAMRIDH acts as an enabler for the emerging companies/startups to take their products or solutions from a prototype stage to commercialization.

Key differences from the healthcare facility:

• The scheme will provide support to selected startups with equity funding up to Rs. 80 lakhs [maximum 40 lakhs from MeitY and Rs 40 lakhs from a co-investor].
• The startup must have a working MVP/POC with a minimum TRL of 3 which is market fit, viable for commercialization, and have scope of scaling. Lower readiness bar than the healthcare facility.
• Works through selected accelerators — these accelerators then select 5-10 startups each in the focused areas of health-tech, ed-tech, agri-tech, consumer-tech, fin-tech, Software as a Service (SaaS), and sustainability.

Think of it as a stepping stone: MeitY SAMRIDH helps you get from prototype to market. SAMRIDH Healthcare helps you get from market to scale.

The Bigger Picture: Why This Matters for Healthcare Founders in 2026

India’s healthtech ecosystem is massive — out of the total 13,995 HealthTech companies in India, 1,654 have secured funding. The market potential is enormous: the digital health market, valued at $14.5–16.1 billion in 2024, is projected to reach $76–107 billion by 2033.

But HealthTech funding remained selective, favoring businesses with strong distribution, digital infrastructure, and repeat usage. Funding is expected to rebound selectively, favoring startups that have demonstrated operational excellence, validated clinical outcomes, and measurable impact.

That word — “selectively” — is the key to understanding why SAMRIDH matters so much right now. In a market where investors are being more careful, having SAMRIDH validation, SAMRIDH capital, and the SAMRIDH network behind you puts you in a fundamentally stronger position than walking into a VC pitch cold.

Most founders ignore government-adjacent programs. Not because the programs are bad. But because nobody ever explained them clearly enough to make them feel real.

SAMRIDH is real. The portfolio is real. The Karma story, the Blackfrog story, the Sunfox story — these are real founders who used this facility to unlock growth they couldn’t have achieved alone. If you’re building something that makes healthcare more accessible, more affordable, or more effective for the people who need it most, this is one of the smartest funding paths you can take.

All information is sourced from SAMRIDH’s official websites (samridhhealth.org, samridh.org), the USAID/NITI Aayog white paper on blended finance, MeitY’s official PIB releases (February 2026), Tracxn, and verified reporting as of April 2026. Eligibility criteria, focus areas, and programme structures may change — always verify directly on the official portals before applying. Note that SAMRIDH Healthcare (USAID/IPE Global) and SAMRIDH MeitY Accelerator are separate programmes with different eligibility requirements and application processes. This article is for informational purposes only and is not affiliated with SAMRIDH, USAID, MeitY, or any government body.